Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS

Sun Yat-sen University logo

Sun Yat-sen University

Status and phase

Completed
Phase 4

Conditions

Ovarian Hyperstimulation Syndrome

Treatments

Drug: letrozole
Drug: Aspirin

Study type

Interventional

Funder types

Other

Identifiers

NCT02670304
28843020

Details and patient eligibility

About

Letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. In 2009, Letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.

Full description

Letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. In this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.

Enrollment

100 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • infertile women undergoing IVF treatment with more than 25 oocytes collected.

Exclusion criteria

  • letrozole contraindications,e.g. severe hepatic and renal dysfunction

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

100 participants in 2 patient groups

letrozole
Experimental group
Description:
letrozole for the first day after ovum picked up at least for 5 days.
Treatment:
Drug: letrozole
aspirin
Active Comparator group
Description:
asprin for the first day after ovum picked up at least for 5 days.
Treatment:
Drug: Aspirin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems